Trial
NCT01545141
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Roswell Park Cancer Institute
Collaborators
AIM ImmunoTech Inc.
Condition
Colorectal Cancer
Intervention
Chemokin Modulatory Regimen (5 MU/m2)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-27